Prognosis of Stage pT0 after Prolonged Neoadjuvant Endocrine Therapy of Prostate Cancer: A Matched-Pair Analysis

European Urology

Volumn 45, Issue 1, 2004, Pages 42-45

  Kollermann, Jens ^a   Hopfenmüller, Werner ^a   Caprano, Jörg ^b   Budde, Anke ^b   Weidenfeld, Helga ^c   Weidenfeld, Michael ^c   Helpap, Burkhard ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Urologic Practice   (Germany)

^c Urologic Practice   (Germany)

^d Hegau Klinikum   (Germany)

Author keywords

Neoadjuvant hormonal treatment; Prostate cancer; PSA progression; pT0

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RELAPSE;

EID: 0346445531     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2003.06.001     Document Type: Article

References (16)

1. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555-65.
2. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-34.
3. Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152:1826-30.
4. Ramos CG, Carvalhal GF, Smith DS, Mager DE, Catalona WJ. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer. J Urol 1999;161:1525-9.
5. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002;90:561-6.
6. Civantos F, Sadek S, Obek C, Lai S, Soloway M. Neoadjuvant hormonal therapy prior to radical prostatectomy. Mol Urol 1999;3:201-4.
7. Klotz LH, Goldenberg SL, Jewett M, Barkin J, Chetner M, Fradet Y, et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. Urology 1999;53:757-63.
8. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000;38:706-13.
9. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood Jr DP, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995;154:424-8.
10. Fair WR, Betancourt JE. Update on Memorial Sloan Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer. Mol Urol 2000;4:241-8.
11. Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994;18:979-91.
12. Cookson MS, Sogani PC, Russo P, Sheinfeld J, Herr H, Dalbagni G, et al. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol 1997;432-8.
13. Köllermann MW, Pantel K, Enzmann T, Feek U, Köllermann J, Kossiwakis M, et al. Supersensitive PSA-monitored neoadjuvant hormone treatment of clinically localized prostate cancer: effects on positive margins, tumor detection and epithelial cells in bone marrow. Eur Urol 1998;34:318-24.
14. Stamey TA, McNeal JE, Freiha FS, Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988;139:1235-41.
15. Köllermann J, Feek U, Muller H, Kaulfuss U, Oehler U, Helpap B, et al. Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma. Eur Urol 2000;38:714-20.
16. Meyer F, Bairati I, Bedard C, Lacombe L, Tetu B, Fradet Y. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer. Urology 2001;58:71-7.